Lipocine Inc. — Q2 2019 Form 10-Q
Business context and reporting period. Lipocine is a clinical-stage biopharmaceutical company developing oral drug candidates. This unaudited filing covers the quarter and six months ended June 30, 2019. Its lead candidate, TLANDO, is an oral testosterone replacement therapy; the company reported no product sales.
Financial performance and position
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $428,031 |
| Research and development expense | $1.96 million | $1.48 million | $3.91 million | $2.86 million |
| General and administrative expense | $1.39 million | $1.68 million | $2.56 million | $3.37 million |
| Operating loss | $3.35 million | $3.16 million | $6.48 million | $5.80 million |
| Net loss | $3.43 million | $3.26 million | $6.66 million | $5.98 million |
| Loss per share | $0.14 | $0.15 | $0.28 | $0.28 |
- Cash and liquidity: At June 30, unrestricted cash, cash equivalents and marketable securities totaled approximately $14.5 million; an additional $5.0 million was restricted as loan collateral. Current assets were $19.64 million and current liabilities $4.44 million.
- Cash flow: For the first half, operating activities used $5.56 million, investing activities used $3.53 million, and financing activities provided $4.68 million. Cash, cash equivalents and restricted cash declined $4.41 million to $8.66 million.
- Debt: Balance-sheet debt was approximately $8.72 million, including current and non-current portions. The SVB loan bears interest at prime plus 1% (6.5% at June 30, 2019), matures December 2021, and is secured by substantially all assets other than specified exclusions. The $5.0 million cash collateral remains restricted until TLANDO receives FDA approval.
- Margins: With no current-period revenue, operating and net profit margins are not meaningful.
Material changes versus prior comparable periods
- Q2 net loss increased approximately $175,000 year over year; first-half net loss increased approximately $680,000.
- First-half R&D expense rose $1.05 million, primarily from TLANDO regulatory and study costs and commencement of the LPCN 1144 Phase 2 study. First-half G&A expense fell $807,000, mainly due to lower personnel costs following elimination of the commercial sales and marketing team.
- The $428,031 of first-half 2018 revenue was a Spriaso royalty; no such royalty was recognized in 2019.
- The company raised $6.34 million net through its at-the-market stock offering in the first half of 2019, selling 2,992,504 shares. Weighted-average sale price was $2.18 per share.
Outlook, commentary and risks
- The FDA accepted TLANDO’s resubmitted NDA and set a November 9, 2019 PDUFA goal date. Management stated that existing capital resources were expected to fund projected operations through at least March 31, 2020, but additional capital would be needed at some point to support operations and development.
- Management estimated approximately $526,000 in additional TLANDO R&D costs to respond to FDA inquiries. It planned to focus 2019 efforts primarily on TLANDO and LPCN 1144; initiation of an LPCN 1107 Phase 3 study was not anticipated in 2019 absent additional capital or an out-license.
- The TLANDO NDA remains subject to regulatory uncertainty, including the possibility of another complete response letter, additional studies, labeling restrictions or post-approval requirements. In the ABPM study, mean 24-hour systolic and diastolic blood pressure increased 3.82 mm Hg and 1.20 mm Hg, respectively; the FDA’s assessment remains material to approval.
- LPCN 1144’s Phase 2 LiFT study was underway, with first subject dosing expected in Q3 2019. A prior proof-of-concept study reported liver-fat reductions, but further clinical results are needed.
- Capital needs could rise if approval is delayed or denied, more studies are required, or the company builds an internal sales force. Financing may be unavailable or dilutive; management warned that inability to raise funds could require delaying, reducing or suspending programs.
- Contingencies include a shareholder derivative lawsuit alleging breaches of fiduciary duty related to TLANDO NDA statements; management recorded no liability because loss was not considered probable or estimable. Clarus appealed the PTAB judgment cancelling claims in its patent, and Lipocine separately sued Clarus alleging that JATENZO infringes Lipocine patents; Clarus asserted non-infringement and invalidity counterclaims.
Important facts for investors to verify
- FDA review outcome and timing for TLANDO, including any additional information requests, approval conditions or post-marketing requirements.
- Cash runway assumptions, spending pace, restricted-cash terms and timing and terms of any additional financing or licensing arrangements.
- Progress, enrollment, costs and results of LPCN 1144’s LiFT Phase 2 study and any planned studies for other candidates.
- SVB debt amortization, interest-rate exposure, covenant compliance and the conditions for release of the $5.0 million collateral.
- Potential dilution from future ATM sales and developments in the derivative and Clarus litigation matters.